The private-credit arm of Guggenheim Investments has employed a novel tool to attract institutional investors to its newest fund as it contends with fierce fundraising competition from other ...

Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...

Guggenheim analyst Shahriar Pourreza maintained a Hold rating on Spire (SR – Research Report) today and set a price target of $67.00. The ...

Immunovant (NASDAQ:IMVT – Get Free Report) had its price target dropped by equities researchers at Guggenheim from $46.00 to ...

Consult a professional regarding your specific legal or tax matters. Guggenheim Investments is the global asset management and investment advisory division of Guggenheim Partners, LLC ...

Guggenheim analyst Robert Drbul maintained a Buy rating on Tapestry (TPR – Research Report) yesterday and set a price target of $90.00. The ...